DexCom has signed an agreement with Google’s life sciences team to jointly develop a new series of continuous glucose monitoring (CGM) products.
The new CGM products being developed will integrate Google’s miniaturized electronics platform with DexCom’s sensor technology.
DexCom president and CEO Kevin Sayer said: "Working together, we believe we can introduce products that will move us beyond our core Type 1 business to become the standard of care for all people living with diabetes."
Google life sciences team head Andrew Conrad said: "This collaboration is another step towards expanding monitoring options and making it easier for people with diabetes to proactively manage their health."
Under the deal, initial products to be developed will focus on reducing both the cost and size of CGM body worn components.
The partnership will design the products that are flexible to be disposable and intended for use across all diabetes markets.
The deal will allow DexCom to retain all sales and distribution rights of the products to be developed under the collaboration.
In addition, DexCom is obligated to pay an initial upfront payment and milestone payments during development, and revenue-based royalties, if achieves a certain level of revenue once these products are launched.